Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000811720 | SCV000952001 | uncertain significance | Cerebral cavernous malformation 2 | 2020-01-11 | criteria provided, single submitter | clinical testing | Experimental studies have shown that this missense change results in significantly reduced solubility in vitro, affecting the stability of the protein (PMID: 25525273). This variant has been observed in an individual with clinical features of cerebral cavernous malformation (PMID: 25525273). This variant is not present in population databases (ExAC no frequency). This sequence change replaces leucine with proline at codon 213 of the CCM2 protein (p.Leu213Pro). The leucine residue is highly conserved and there is a moderate physicochemical difference between leucine and proline. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Swedish Neurofibromatosis Center, |
RCV000991327 | SCV001132047 | likely pathogenic | Cerebral cavernous malformation | 2019-12-18 | criteria provided, single submitter | clinical testing | 1. This sequence change replaces leucine with proline at codon 213 of the CCM2 protein (p.Leu213Pro). The leucine residue is highly conserved and there is a moderate physicochemical difference between leucine and proline. 2. This variant is not present in population databases (ExAC no frequency). 3. This variant has been observed in an individual with clinical features of cerebral cavernous malformation (PMID: 25525273). 4. Experimental studies have shown that this missense change results in significantly reduced solubility in vitro, affecting the stability of the protein (PMID: 25525273). |